Free Trial
NASDAQ:QNRX

Quoin Pharmaceuticals Q2 2024 Earnings Report

Quoin Pharmaceuticals logo
$7.11 +0.20 (+2.89%)
Closing price 08/8/2025 03:53 PM Eastern
Extended Trading
$7.16 +0.05 (+0.77%)
As of 08/8/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quoin Pharmaceuticals EPS Results

Actual EPS
-$13.65
Consensus EPS
-$26.25
Beat/Miss
Beat by +$12.60
One Year Ago EPS
-$74.55

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

Earnings Documents

Quoin Pharmaceuticals Earnings Headlines

Quoin (QNRX) Q2 Loss Beats Estimates
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX), Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

View Quoin Pharmaceuticals Profile

More Earnings Resources from MarketBeat